Filing Flows › Starling Oncology (STLN) › Q2 2026 › vs Q1 2026
Starling Oncology (STLN) Q2 2026 vs Q1 2026 (quarter over quarter)
Starling Oncology's revenue rose $13.8M (+9%) from $147M in Q1 2026 to $161M in Q2 2026. The biggest changes: Specialty Pharmacy +$11.1M (+13%); Clinical trials & other +$3.0M (+373%); Patient services −$260K (-0.4%).
Starling Oncology, Q2 2026: revenue $161M (+35% year over year), operating margin -2.9%, net loss $9.8M, operating cash flow $11.9M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 6.8% | -2.2% | +9.0 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| FFS revenue | $30.9M | $32.2M | −$1.3M | -4% |
| Capitated revenue | $28.0M | $26.9M | $1.0M | +4% |
| Patient services | $58.8M | $59.1M | −$260K | -0.4% |
| Specialty Pharmacy | $98.6M | $87.5M | $11.1M | +13% |
| Clinical trials & other | $3.8M | $813K | $3.0M | +373% |
| Revenue | $161M | $147M | $13.8M | +9% |
| Net loss | $9.8M | $2.5M | $7.3M | +293% |
| Costs & expenses | $171M | $154M | $17.1M | +11% |
| Operating costs | $166M | $154M | $11.9M | +8% |
| Interest & other, net | $5.2M | −$4.0M | $9.2M | — |
| SG&A | $29.9M | $28.2M | $1.7M | +6% |
| Other operating costs | $136M | $126M | $10.2M | +8% |
| Operating cash sources | $21.7M | $277K | $21.5M | 78× |
| Depreciation & amortization | $1.8M | $1.6M | $222K | +14% |
| Share-based compensation | $1.1M | $1.7M | −$616K | -37% |
| Working capital & other | $18.8M | −$3.0M | $21.8M | — |
| Net loss absorbed | $9.8M | $2.5M | $7.3M | +293% |
| Operating cash flow | $11.9M | −$2.2M | $14.2M | — |
| Free cash flow (OCF − capex) | $11.0M | −$3.3M | $14.3M | — |
| Capital expenditures | $908K | $1.0M | −$134K | -13% |
Questions
How much did Starling Oncology's revenue grow quarter over quarter in Q2 2026?
Starling Oncology's revenue rose $13.8M (+9%) from $147M in Q1 2026 to $161M in Q2 2026.
What drove Starling Oncology's revenue change in Q2 2026?
Specialty Pharmacy +$11.1M (+13%); Clinical trials & other +$3.0M (+373%); Patient services −$260K (-0.4%).